Inventiva annonce un financement allant jusqu’à 348 millions d'euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH
October 14, 2024 02:30 ET
|
INVENTIVA
► Inventiva obtient 94,1 millions d’euros dans le cadre d’un financement en plusieurs tranches d'un montant maximum de 348 millions d'euros, sous réserve de la réalisation de certaines conditions,...
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
October 14, 2024 02:30 ET
|
INVENTIVA
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million...
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
More than 50 organizations choose Truveta for the most complete, timely, and clean EHR data to study safety and effectiveness, improve patient care, and train medical AI
October 23, 2023 09:00 ET
|
Truveta
Bellevue, WASH., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Truveta announced today that it is partnering with more than 50 organizations in life sciences, healthcare, government, academic medical centers,...
Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
September 20, 2023 16:00 ET
|
INVENTIVA
Hepalys Pharma, Inc. est une nouvelle société créée par Catalys Pacific, et dans laquelle Inventiva détient une participation de 30%. Dans le cadre de l’accord de licence exclusif, Inventiva...
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
September 20, 2023 16:00 ET
|
INVENTIVA
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million...
Inventiva publie ses résultats annuels 2022
March 29, 2023 16:00 ET
|
INVENTIVA
Trésorerie et équivalents de trésorerie de 86,7 millions d'euros et dépôts à court terme de 1 million d'euros au 31 décembre 2022, contre respectivement 86,6 millions d'euros et 8,8 millions d'euros...
Inventiva reports its 2022 full-year results
March 29, 2023 16:00 ET
|
INVENTIVA
Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 ...
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunie le 25 janvier 2023
January 26, 2023 02:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 26 janvier 2023 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de...
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
January 26, 2023 02:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...